Rare-19. Multicenter, Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas: An Nf Clinical Trials Consortium Study

Abstract

NEURO-ONCOLOGY • NOVEMBER 2017 able cases BRAF mutation was noted. Adjuvant radiation was delivered in 67 (27.7%) patients. Estimated median PFS was 48.3 months. In univariate analysis younger patients (≤20 years) had better PFS compared to elder [103.2 vs 36 months (p= .013]. Patients with GTR and grade II tumor had better PFS than STR and grade III tumor [84 vs14 months; p=0.001]; [48 vs 11.7 months p=0.000]. Ki 67 index ≤5% conferred better PFS [144 vs 17 months; p=0.250]. Estimated median OS was 209.0 months. In univariate analysis younger patients (≤20 years) found to have better OS [300 vs 209 months; p=.001]. Patients with a GTR and grade II tumor had a significantly better OS than STR (p=0.001) or with a grade III tumor [209 vs 49 months; p=0.001]. A lower Ki 67 index of ≤5% conferred a better OS [168 vs 49 months; p=0.08]. OS was significantly worse for patients treated with adjuvant radiation (p=0.007). CONCLUSION: Patients with younger age, GTR, grade II tumor and lower MIB have a better survival.

The impact of Bevacizumab on mucosal healing after dental extraction in patients undergoing cancer treatment in the central region of Algeria

“…Moreover, complications related to wound healing have been well-documented in patients undergoing anti-angiogenic treatment. This result has been strongly supported by studies like those conducted by Ahn et al, 23 Plotkins et al, 24 and also Clark et al, 25 which have shown results that appear similar to ours, highlighting complications in wound healing among patients treated with anti-angiogenics. Furthermore, both human and animal histopathological studies have demonstrated a decrease in endothelial cells and macrophages, reduced neovascularization, disruption of re-epithelialization, and impairment of wound healing [26][27][28] .…”

Schwannomatosis: a Realm Reborn: year one

“…A recent study has tackled the question of maintenance therapy with Bevacizumab in a prospective trial of 20 patients receiving 5 mg/kg every 3 weeks for 18 months. They demonstrated that low-dose Bevacizumab remained effective in preventing hearing decline (70% of freedom from hearing loss after 98 weeks) and tumor growth (89% of freedom from tumor growth after 98 weeks) while maintaining quality of life and offering good tolerance, with three participants (15%) discontinuing treatment due to adverse events [35 ▪ ].…”